Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]J. H. Hoeijmakers: DNA damage, aging, and cancer. N Engl J Med, 361(15), 1475-85 (2009)

  • [2]S. D. McCulloch and T. A. Kunkel: The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res, 18(1), 148-61 (2008)

  • [3]A. Ciccia and S. J. Elledge: The DNA damage response: making it safe to play with knives. Mol Cell, 40(2), 179-204 (2010)

  • [4]J. L. Ravanat, T. Douki and J. Cadet: Direct and indirect effects of UV radiation on DNA and its components. J Photochem Photobiol B, 63(1-3), 88-102 (2001)

  • [5]J. F. Ward: DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability. Prog Nucleic Acid Res Mol Biol, 35, 95-125 (1988)

  • [6]M. A. Kang, E. Y. So, A. L. Simons, D. R. Spitz and T. Ouchi: DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway. Cell Death Dis, 3, e249 (2012)

  • [7]M. F. Lavin: ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene, 26(56), 7749-58 (2007)

  • [8]J. Falck, J. Coates and S. P. Jackson: Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature, 434(7033), 605-11 (2005)

  • [9]J. H. Lee and T. T. Paull: ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science, 308(5721), 551-4 (2005)

  • [10]T. Uziel, Y. Lerenthal, L. Moyal, Y. Andegeko, L. Mittelman and Y. Shiloh: Requirement of the MRN complex for ATM activation by DNA damage. EMBO J, 22(20), 5612-21 (2003)

  • [11]D. Cortez, S. Guntuku, J. Qin and S. J. Elledge: ATR and ATRIP: partners in checkpoint signaling. Science, 294(5547), 1713-6 (2001)

  • [12]L. Zou and S. J. Elledge: Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science, 300(5625), 1542-8 (2003)

  • [13]J. C. Harrison and J. E. Haber: Surviving the breakup: the DNA damage checkpoint. Annu Rev Genet, 40, 209-35 (2006)

  • [14]J. W. Harper and S. J. Elledge: The DNA damage response: ten years after. Mol Cell, 28(5), 739-45 (2007)

  • [15]J. Bartek and J. Lukas: Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3(5), 421-9 (2003)

  • [16]D. Cortez, Y. Wang, J. Qin and S. J. Elledge: Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science, 286(5442), 1162-6 (1999)

  • [17]S. T. Kim, B. Xu and M. B. Kastan: Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. Genes Dev, 16(5), 560-70 (2002)

  • [18]J. Lukas, C. Lukas and J. Bartek: Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst), 3(8-9), 997-1007 (2004)

  • [19]G. Iliakis, Y. Wang, J. Guan and H. Wang: DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene, 22(37), 5834-47 (2003)

  • [20]M. B. Kastan and J. Bartek: Cell-cycle checkpoints and cancer. Nature, 432(7015), 316-23 (2004)

  • [21]B. B. Zhou and S. J. Elledge: The DNA damage response: putting checkpoints in perspective. Nature, 408(6811), 433-9 (2000)

  • [22]F. Altieri, C. Grillo, M. Maceroni and S. Chichiarelli: DNA damage and repair: from molecular mechanisms to health implications. Antioxid Redox Signal, 10(5), 891-937 (2008)

  • [23]K. K. Khanna and S. P. Jackson: DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet, 27(3), 247-54 (2001)

  • [24]D. C. van Gent, J. H. Hoeijmakers and R. Kanaar: Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet, 2(3), 196-206 (2001)

  • [25]A. J. Hartlerode and R. Scully: Mechanisms of double-strand break repair in somatic mammalian cells. Biochem J, 423(2), 157-68 (2009)

  • [26]B. Pardo, B. Gomez-Gonzalez and A. Aguilera: DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship. Cell Mol Life Sci, 66(6), 1039-56 (2009)

  • [27]X. Li and W. D. Heyer: Homologous recombination in DNA repair and DNA damage tolerance. Cell Res, 18(1), 99-113 (2008)

  • [28]Z. Mao, M. Bozzella, A. Seluanov and V. Gorbunova: DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle, 7(18), 2902-6 (2008)

  • [29]M. R. Lieber: The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem, 79, 181-211 (2010)

  • [30]O. Surova and B. Zhivotovsky: Various modes of cell death induced by DNA damage. Oncogene, 32(33), 3789-97 (2013)

  • [31]L. Hayflick: The Limited in vitro Lifetime of Human Diploid Cell Strains. Exp Cell Res, 37, 614-36 (1965)

  • [32]L. Hayflick and P. S. Moorhead: The serial cultivation of human diploid cell strains. Exp Cell Res, 25, 585-621 (1961)

  • [33]V. C. Gray-Schopfer, S. C. Cheong, H. Chong, J. Chow, T. Moss, Z. A. Abdel-Malek, R. Marais, D. Wynford-Thomas and D. C. Bennett: Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer, 95(4), 496-505 (2006)

  • [34]R. Di Micco, M. Fumagalli, A. Cicalese, S. Piccinin, P. Gasparini, C. Luise, C. Schurra, M. Garre, P. G. Nuciforo, A. Bensimon, R. Maestro, P. G. Pelicci and F. d’Adda di Fagagna: Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature, 444(7119), 638-42 (2006)

  • [35]W. J. Mooi and D. S. Peeper: Oncogene-induced cell senescence--halting on the road to cancer. N Engl J Med, 355(10), 1037-46 (2006)

  • [36]Z. Chen, L. C. Trotman, D. Shaffer, H. K. Lin, Z. A. Dotan, M. Niki, J. A. Koutcher, H. I. Scher, T. Ludwig, W. Gerald, C. Cordon-Cardo and P. P. Pandolfi: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 436(7051), 725-30 (2005)

  • [37]A. Shamma, Y. Takegami, T. Miki, S. Kitajima, M. Noda, T. Obara, T. Okamoto and C. Takahashi: Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell, 15(4), 255-69(2009)1

  • [38]C. Gewinner, Z. C. Wang, A. Richardson, J. Teruya-Feldstein, D. Etemadmoghadam, D. Bowtell, J. Barretina, W. M. Lin, L. Rameh, L. Salmena, P. P. Pandolfi and L. C. Cantley: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell, 16(2), 115-25 (2009)

  • [39]J. G. Jackson and O. M. Pereira-Smith: p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. Cancer Res, 66(17), 8356-60 (2006)

  • [40]J. M. Espinosa, R. E. Verdun and B. M. Emerson: p53 functions through stress-and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell, 12(4), 1015-27 (2003)

  • [41]I. P. Trougakos, A. Saridaki, G. Panayotou and E. S. Gonos: Identification of differentially expressed proteins in senescent human embryonic fibroblasts. Mech Ageing Dev, 127(1), 88-92 (2006)

  • [42]E. B. Golden, I. Pellicciotta, S. Demaria, M. H. Barcellos-Hoff and S. C. Formenti: The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol, 2, 88(2012)

  • [43]G. P. Dimri, X. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelley, E. E. Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith and et al.: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A, 92(20), 9363-7 (1995)

  • [44]U. Herbig, M. Ferreira, L. Condel, D. Carey and J. M. Sedivy: Cellular senescence in aging primates. Science, 311(5765), 1257(2006)

  • [45]F. Rodier, D. P. Munoz, R. Teachenor, V. Chu, O. Le, D. Bhaumik, J. P. Coppe, E. Campeau, C. M. Beausejour, S. H. Kim, A. R. Davalos and J. Campisi: DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci, 124(Pt 1), 68-81 (2011)

  • [46]G. Kroemer, L. Galluzzi, P. Vandenabeele, J. Abrams, E. S. Alnemri, E. H. Baehrecke, M. V. Blagosklonny, W. S. El-Deiry, P. Golstein, D. R. Green, M. Hengartner, R. A. Knight, S. Kumar, S. A. Lipton, W. Malorni, G. Nunez, M. E. Peter, J. Tschopp, J. Yuan, M. Piacentini, B. Zhivotovsky, G. Melino and D. Nomenclature Committee on Cell: Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ, 16(1), 3-11 (2009)

  • [47]A. Barascu, C. Le Chalony, G. Pennarun, D. Genet, N. Imam, B. Lopez and P. Bertrand: Oxidative stress induces an ATM-independent senescence pathway through p38 MAPK-mediated lamin B1 accumulation. EMBO J, 31(5), 1080-94 (2012)

  • [48]Q. M. Chen, K. R. Prowse, V. C. Tu, S. Purdom and M. H. Linskens: Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts. Exp Cell Res, 265(2), 294-303 (2001)

  • [49]S. Parrinello, E. Samper, A. Krtolica, J. Goldstein, S. Melov and J. Campisi: Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell Biol, 5(8), 741-7 (2003)

  • [50]D. X. Mason, T. J. Jackson and A. W. Lin: Molecular signature of oncogenic ras-induced senescence. Oncogene, 23(57), 9238-46 (2004)

  • [51]D. N. Shelton, E. Chang, P. S. Whittier, D. Choi and W. D. Funk: Microarray analysis of replicative senescence. Curr Biol, 9(17), 939-45 (1999)

  • [52]J. P. Coppe, P. Y. Desprez, A. Krtolica and J. Campisi: The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol, 5, 99-118 (2010)

  • [53]T. Kuilman, C. Michaloglou, L. C. Vredeveld, S. Douma, R. van Doorn, C. J. Desmet, L. A. Aarden, W. J. Mooi and D. S. Peeper: Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell, 133(6), 1019-31 (2008)

  • [54]J. C. Acosta, A. O’Loghlen, A. Banito, M. V. Guijarro, A. Augert, S. Raguz, M. Fumagalli, M. Da Costa, C. Brown, N. Popov, Y. Takatsu, J. Melamed, F. d’Adda di Fagagna, D. Bernard, E. Hernando and J. Gil: Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell, 133(6), 1006-18 (2008)

  • [55]A. Freund, C. K. Patil and J. Campisi: p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J, 30(8), 1536-48 (2011)

  • [56]A. V. Orjalo, D. Bhaumik, B. K. Gengler, G. K. Scott and J. Campisi: Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A, 106(40), 17031-6 (2009)

  • [57]R. M. Laberge, Y. Sun, A. V. Orjalo, C. K. Patil, A. Freund, L. Zhou, S. C. Curran, A. R. Davalos, K. A. Wilson-Edell, S. Liu, C. Limbad, M. Demaria, P. Li, G. B. Hubbard, Y. Ikeno, M. Javors, P. Y. Desprez, C. C. Benz, P. Kapahi, P. S. Nelson and J. Campisi: MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol, 17(8), 1049-61 (2015)

  • [58]N. Herranz, S. Gallage, M. Mellone, T. Wuestefeld, S. Klotz, C. J. Hanley, S. Raguz, J. C. Acosta, A. J. Innes, A. Banito, A. Georgilis, A. Montoya, K. Wolter, G. Dharmalingam, P. Faull, T. Carroll, J. P. Martinez-Barbera, P. Cutillas, F. Reisinger, M. Heikenwalder, R. A. Miller, D. Withers, L. Zender, G. J. Thomas and J. Gil: mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat Cell Biol, 17(9), 1205-17 (2015)

  • [59]H. L. Pahl: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 18(49), 6853-66 (1999)

  • [60]A. Lasry and Y. Ben-Neriah: Senescence-associated inflammatory responses: aging and cancer perspectives. Trends Immunol, 36(4), 217-28 (2015)

  • [61]C. Nathan: Points of control in inflammation. Nature, 420(6917), 846-52 (2002)

  • [62]M. Philip, D. A. Rowley and H. Schreiber: Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol, 14(6), 433-9 (2004)

  • [63]M. Karin and F. R. Greten: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5(10), 749-59 (2005)

  • [64]M. Karin, T. Lawrence and V. Nizet: Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell, 124(4), 823-35 (2006)

  • [65]R. Medzhitov: Origin and physiological roles of inflammation. Nature, 454(7203), 428-435 (2008)

  • [66]M. Keller, A. Rüegg, S. Werner and H.-D. Beer: Active Caspase-1 Is a Regulator of Unconventional Protein Secretion. Cell, 132(5), 818-831 (2008)

  • [67]O. Takeuchi and S. Akira: Pattern recognition receptors and inflammation. Cell, 140(6), 805-20 (2010)

  • [68]J. S. Arthur and S. C. Ley: Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol, 13(9), 679-92 (2013)

  • [69]S. L. Foster, D. C. Hargreaves and R. Medzhitov: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature, 447(7147), 972-8 (2007)

  • [70]V. R. Ramirez-Carrozzi, A. A. Nazarian, C. C. Li, S. L. Gore, R. Sridharan, A. N. Imbalzano and S. T. Smale: Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev, 20(3), 282-96 (2006)

  • [71]G. Bonizzi and M. Karin: The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol, 25(6), 280-8 (2004)

  • [72]S. Ghosh and M. S. Hayden: Celebrating 25 years of NF-kappaB research. Immunol Rev, 246(1), 5-13 (2012)

  • [73]M. Pasparakis: Role of NF-kappaB in epithelial biology. Immunol Rev, 246(1), 346-58 (2012)

  • [74]M. Karin: Nuclear factor-kappaB in cancer development and progression. Nature, 441(7092), 431-6 (2006)

  • [75]A. Iwasaki and R. Medzhitov: Control of adaptive immunity by the innate immune system. Nat Immunol, 16(4), 343-53 (2015)

  • [76]A. T. Lau, Y. Wang and J. F. Chiu: Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem, 104(2), 657-67 (2008)

  • [77]M. Merad, P. Sathe, J. Helft, J. Miller and A. Mortha: The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol, 31, 563-604 (2013)

  • [78]S. E. Headland and L. V. Norling: The resolution of inflammation: Principles and challenges. Seminars in Immunology(0) (2015)

  • [79]T. S. Gastardelo, A. S. Damazo, J. Dalli, R. J. Flower, M. Perretti and S. M. Oliani: Functional and Ultrastructural Analysis of Annexin A1 and Its Receptor in Extravasating Neutrophils during Acute Inflammation. The American Journal of Pathology, 174(1), 177-183 (2009)

  • [80]D. El Kebir, L. Jozsef, T. Khreiss, W. Pan, N. A. Petasis, C. N. Serhan and J. G. Filep: Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J Immunol, 179(1), 616-22 (2007)

  • [81]P. Maderna, D. C. Cottell, T. Toivonen, N. Dufton, J. Dalli, M. Perretti and C. Godson: FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J, 24(11), 4240-9 (2010)

  • [82]M. Scannell, M. B. Flanagan, A. deStefani, K. J. Wynne, G. Cagney, C. Godson and P. Maderna: Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol, 178(7), 4595-605 (2007)

  • [83]K. E. Blume, S. Soeroes, M. Waibel, H. Keppeler, S. Wesselborg, M. Herrmann, K. Schulze-Osthoff and K. Lauber: Cell surface externalization of annexin A1 as a failsafe mechanism preventing inflammatory responses during secondary necrosis. J Immunol, 183(12), 8138-47 (2009)

  • [84]J. Bystrom, I. Evans, J. Newson, M. Stables, I. Toor, N. van Rooijen, M. Crawford, P. Colville-Nash, S. Farrow and D. W. Gilroy: Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood, 112(10), 4117-27 (2008)

  • [85]S. Gordon: Alternative activation of macrophages. Nat Rev Immunol, 3(1), 23-35 (2003)

  • [86]S. Schif-Zuck, N. Gross, S. Assi, R. Rostoker, C. N. Serhan and A. Ariel: Saturated-efferocytosis generates pro-resolving CD11blow macrophages: Modulation by resolvins and glucocorticoids. European Journal of Immunology, 41(2), 366-379 (2011)

  • [87]M.-L. N. Huynh, V. A. Fadok and P. M. Henson: Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. The Journal of Clinical Investigation, 109(1), 41-50 (2002)

  • [88]C. N. Serhan and J. Savill: Resolution of inflammation: the beginning programs the end. Nat Immunol, 6(12), 1191-7 (2005)

  • [89]R. Rajakariar, T. Lawrence, J. Bystrom, M. Hilliard, P. Colville-Nash, G. Bellingan, D. Fitzgerald, M. M. Yaqoob and D. W. Gilroy: Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood, 111(8), 4184-92 (2008)

  • [90]A. Ariel, N. Chiang, M. Arita, N. A. Petasis and C. N. Serhan: Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol, 170(12), 6266-72 (2003)

  • [91]T. Lawrence, M. Bebien, G. Y. Liu, V. Nizet and M. Karin: IKK(alpha) limits macrophage NF-(kappa)B activation and contributes to the resolution of inflammation. Nature, 434(7037), 1138-1143 (2005)

  • [92]D. L. Boone, E. E. Turer, E. G. Lee, R.-C. Ahmad, M. T. Wheeler, C. Tsui, P. Hurley, M. Chien, S. Chai, O. Hitotsumatsu, E. McNally, C. Pickart and A. Ma: The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol, 5(10), 1052-1060 (2004)

  • [93]W. S. Alexander and D. J. Hilton: The Role of Suppressors of Cytokine Signaling (SOCS) Proteins in Regulation of the Immune Response. Annual Review of Immunology, 22(1), 503-529 (2004)

  • [94]W. Xue, L. Zender, C. Miething, R. A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo and S. W. Lowe: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature, 445(7128), 656-60 (2007)

  • [95]T. W. Kang, T. Yevsa, N. Woller, L. Hoenicke, T. Wuestefeld, D. Dauch, A. Hohmeyer, M. Gereke, R. Rudalska, A. Potapova, M. Iken, M. Vucur, S. Weiss, M. Heikenwalder, S. Khan, J. Gil, D. Bruder, M. Manns, P. Schirmacher, F. Tacke, M. Ott, T. Luedde, T. Longerich, S. Kubicka and L. Zender: Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature, 479(7374), 547-51 (2011)

  • [96]Y. Chien, C. Scuoppo, X. Wang, X. Fang, B. Balgley, J. E. Bolden, P. Premsrirut, W. Luo, A. Chicas, C. S. Lee, S. C. Kogan and S. W. Lowe: Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev, 25(20), 2125-36 (2011)

  • [97]A. Bitto, C. Sell, E. Crowe, A. Lorenzini, M. Malaguti, S. Hrelia and C. Torres: Stress-induced senescence in human and rodent astrocytes. Exp Cell Res, 316(17), 2961-8 (2010)

  • [98]A. Salminen, J. Ojala, K. Kaarniranta, A. Haapasalo, M. Hiltunen and H. Soininen: Astrocytes in the aging brain express characteristics of senescence-associated secretory phenotype. Eur J Neurosci, 34(1), 3-11 (2011)

  • [99]S. Roberts, E. H. Evans, D. Kletsas, D. C. Jaffray and S. M. Eisenstein: Senescence in human intervertebral discs. Eur Spine J, 15 Suppl 3, S312-6 (2006)

  • [100]A. Shane Anderson and R. F. Loeser: Why is osteoarthritis an age-related disease? Best Pract Res Clin Rheumatol, 24(1), 15-26 (2010)

  • [101]B. Bhatia, A. S. Multani, L. Patrawala, X. Chen, T. Calhoun-Davis, J. Zhou, L. Schroeder, R. Schneider-Broussard, J. Shen, S. Pathak, S. Chang and D. G. Tang: Evidence that senescent human prostate epithelial cells enhance tumorigenicity: cell fusion as a potential mechanism and inhibition by p16INK4a and hTERT. Int J Cancer, 122(7), 1483-95 (2008)

  • [102]A. Krtolica, S. Parrinello, S. Lockett, P. Y. Desprez and J. Campisi: Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A, 98(21), 12072-7 (2001)

  • [103]D. Liu and P. J. Hornsby: Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res, 67(7), 3117-26 (2007)

  • [104]M. Rielland, D. J. Cantor, R. Graveline, C. Hajdu, L. Mara, D. Diaz Bde, G. Miller and G. David: Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. J Clin Invest, 124(5), 2125-35 (2014)

  • [105]J. S. Price, J. G. Waters, C. Darrah, C. Pennington, D. R. Edwards, S. T. Donell and I. M. Clark: The role of chondrocyte senescence in osteoarthritis. Aging Cell, 1(1), 57-65 (2002)

  • [106]E. Vasile, Y. Tomita, L. F. Brown, O. Kocher and H. F. Dvorak: Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J, 15(2), 458-66 (2001)

  • [107]C. Matthews, I. Gorenne, S. Scott, N. Figg, P. Kirkpatrick, A. Ritchie, M. Goddard and M. Bennett: Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res, 99(2), 156-64 (2006)

  • [108]J. C. Jeyapalan, M. Ferreira, J. M. Sedivy and U. Herbig: Accumulation of senescent cells in mitotic tissue of aging primates. Mech Ageing Dev, 128(1), 36-44 (2007)

  • [109]P. J. Linton and K. Dorshkind: Age-related changes in lymphocyte development and function. Nat Immunol, 5(2), 133-9 (2004)

  • [110]A. C. Shaw, S. Joshi, H. Greenwood, A. Panda and J. M. Lord: Aging of the innate immune system. Curr Opin Immunol, 22(4), 507-13 (2010)

  • [111]J. Campisi: Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell, 120(4), 513-22 (2005)

  • [112]C. Bavik, I. Coleman, J. P. Dean, B. Knudsen, S. Plymate and P. S. Nelson: The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res, 66(2), 794-802 (2006)

  • [113]J. P. Coppe, K. Kauser, J. Campisi and C. M. Beausejour: Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem, 281(40), 29568-74 (2006)

  • [114]T. K. Dilley, G. T. Bowden and Q. M. Chen: Novel mechanisms of sublethal oxidant toxicity: induction of premature senescence in human fibroblasts confers tumor promoter activity. Exp Cell Res, 290(1), 38-48 (2003)

  • [115]D. Yang, S. G. Elner, Z. M. Bian, G. O. Till, H. R. Petty and V. M. Elner: Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res, 85(4), 462-72 (2007)

  • [116]I. L. Aivaliotis, I. S. Pateras, M. Papaioannou, C. Glytsou, K. Kontzoglou, E. O. Johnson and V. Zoumpourlis: How do cytokines trigger genomic instability? J Biomed Biotechnol, 2012, 536761 (2012)

  • [117]J. Campisi, J. K. Andersen, P. Kapahi and S. Melov: Cellular senescence: a link between cancer and age-related degenerative disease? Semin Cancer Biol, 21(6), 354-9 (2011)

  • [118]S. Vasto, G. Candore, C. R. Balistreri, M. Caruso, G. Colonna-Romano, M. P. Grimaldi, F. Listi, D. Nuzzo, D. Lio and C. Caruso: Inflammatory networks in ageing, age-related diseases and longevity. Mech Ageing Dev, 128(1), 83-91 (2007)

  • [119]L. Ferrucci, A. Ble, S. Bandinelli, F. Lauretani, K. Suthers and J. M. Guralnik: A flame burning within. Aging Clin Exp Res, 16(3), 240-3 (2004)

  • [120]G. Nelson, J. Wordsworth, C. Wang, D. Jurk, C. Lawless, C. Martin-Ruiz and T. von Zglinicki: A senescent cell bystander effect: senescence-induced senescence. Aging Cell, 11(2), 345-9 (2012)

  • [121]D. Hanahan and R. A. Weinberg: Hallmarks of cancer: the next generation. Cell, 144(5), 646-74 (2011)

  • [122]O. Brostrom, R. Lofberg, B. Nordenvall, A. Ost and G. Hellers: The risk of colorectal cancer in ulcerative colitis. An epidemiologic study. Scand J Gastroenterol, 22(10), 1193-9 (1987)

  • [123]S. R. Hamilton: Colorectal carcinoma in patients with Crohn’s disease. Gastroenterology, 89(2), 398-407 (1985)

  • [124]T. Hagemann, F. Balkwill and T. Lawrence: Inflammation and cancer: a double-edged sword. Cancer Cell, 12(4), 300-1 (2007)

  • [125]N. Figueiredo, A. Chora, H. Raquel, N. Pejanovic, P. Pereira, B. Hartleben, A. Neves-Costa, C. Moita, D. Pedroso, A. Pinto, S. Marques, H. Faridi, P. Costa, R. Gozzelino, J. L. Zhao, M. P. Soares, M. Gama-Carvalho, J. Martinez, Q. Zhang, G. Doring, M. Grompe, J. P. Simas, T. B. Huber, D. Baltimore, V. Gupta, D. R. Green, J. A. Ferreira and L. F. Moita: Anthracyclines induce DNA damage response-mediated protection against severe sepsis. Immunity, 39(5), 874-84 (2013)

  • [126]B. Frischholz, R. Wunderlich, P. F. Ruhle, C. Schorn, F. Rodel, L. Keilholz, R. Fietkau, U. S. Gaipl and B. Frey: Reduced secretion of the inflammatory cytokine IL-1beta by stimulated peritoneal macrophages of radiosensitive Balb/c mice after exposure to 0.5. or 0.7.Gy of ionizing radiation. Autoimmunity (2013)

  • [127]O. J. Ott, M. Niewald, H. D. Weitmann, I. Jacob, I. A. Adamietz, U. Schaefer, L. Keilholz, R. Heyd, R. Muecke and D. German Cooperative Group on Radiotherapy for Benign: DEGRO guidelines for the radiotherapy of non-malignant disorders: Part II: Painful degenerative skeletal disorders. Strahlenther Onkol (2014)

  • [128]M. H. Seegenschmiedt, A. Katalinic, H. B. Makoski, W. Haase, G. Gademann and E. Hassenstein: (Radiotherapy of benign diseases: a pattern of care study in Germany). Strahlenther Onkol, 175(11), 541-7 (1999)

  • [129]M. H. Seegenschmiedt, O. Micke and N. Willich: Radiation therapy for nonmalignant diseases in Germany. Current concepts and future perspectives. Strahlenther Onkol, 180(11), 718-30 (2004)

  • [130]O. J. Ott, S. Hertel, U. S. Gaipl, B. Frey, M. Schmidt and R. Fietkau: Benign painful shoulder syndrome: initial results of a single-center prospective randomized radiotherapy dose-optimization trial. Strahlenther Onkol, 188(12), 1108-13 (2012)

  • [131]O. J. Ott, S. Hertel, U. S. Gaipl, B. Frey, M. Schmidt and R. Fietkau: The Erlangen Dose Optimization trial for low-dose radiotherapy of benign painful elbow syndrome. Long-term results. Strahlenther Onkol, 190(3), 293-7 (2014)

  • [132]O. J. Ott, C. Jeremias, U. S. Gaipl, B. Frey, M. Schmidt and R. Fietkau: Radiotherapy for calcaneodynia. Results of a single center prospective randomized dose optimization trial. Strahlenther Onkol, 189(4), 329-34 (2013)

  • [133]O. J. Ott, C. Jeremias, U. S. Gaipl, B. Frey, M. Schmidt and R. Fietkau: Radiotherapy for achillodynia: results of a single-center prospective randomized dose-optimization trial. Strahlenther Onkol, 189 (2), 142-6 (2013)

  • [134]F. Rodel, D. Hofmann, J. Auer, L. Keilholz, M. Rollinghoff, R. Sauer and H. U. Beuscher: The anti-inflammatory effect of low-dose radiation therapy involves a diminished CCL20 chemokine expression and granulocyte/endothelial cell adhesion. Strahlenther Onkol, 184(1), 41-7 (2008)

  • [135]P. Kern, L. Keilholz, C. Forster, M. H. Seegenschmiedt, R. Sauer and M. Herrmann: In vitro apoptosis in peripheral blood mononuclear cells induced by low-dose radiotherapy displays a discontinuous dose-dependence. Int J Radiat Biol, 75(8), 995-1003 (1999)

  • [136]B. Lodermann, R. Wunderlich, S. Frey, C. Schorn, S. Stangl, F. Rodel, L. Keilholz, R. Fietkau, U. S. Gaipl and B. Frey: Low dose ionising radiation leads to a NF-kappaB dependent decreased secretion of active IL-1beta by activated macrophages with a discontinuous dose-dependency. Int J Radiat Biol, 88(10), 727-34 (2012)

  • [137]R. Wunderlich, A. Ernst, F. Rodel, R. Fietkau, O. Ott, K. Lauber, B. Frey and U. S. Gaipl: Low and moderate dose of ionising radiation up to 2 Gy modulates transmigration and chemotaxis of activated macrophages, provokes an anti-inflammatory cytokine milieu, but does not impact on viability and phagocytic function. Clin Exp Immunol (2014)

  • [138]M. Orth, K. Lauber, M. Niyazi, A. A. Friedl, M. Li, C. Maihofer, L. Schuttrumpf, A. Ernst, O. M. Niemoller and C. Belka: Current concepts in clinical radiation oncology. Radiat Environ Biophys, 53(1), 1-29 (2014)

  • [139]U. S. Gaipl, G. Multhoff, H. Scheithauer, K. Lauber, S. Hehlgans, B. Frey and F. Rodel: Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy, 6(5), 597-610 (2014)

  • [140]H. E. Barker, J. T. Paget, A. A. Khan and K. J. Harrington: The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer, 15(7), 409-25 (2015)

  • [141]K. R. Jones, L. W. Elmore, C. Jackson-Cook, G. Demasters, L. F. Povirk, S. E. Holt and D. A. Gewirtz: p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol, 81(6), 445-58 (2005)

  • [142]R. S. Roberson, S. J. Kussick, E. Vallieres, S. Y. Chen and D. Y. Wu: Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res, 65(7), 2795-803 (2005)

  • [143]S. Chakradeo, L. W. Elmore and D. A. Gewirtz: Is senescence reversible? Curr Drug Targets (2015)

  • [144]M. Hollstein, D. Sidransky, B. Vogelstein and C. C. Harris: p53 mutations in human cancers. Science, 253 (5015), 49-53 (1991)

  • [145]K. K. Tsai, J. Stuart, Y. Y. Chuang, J. B. Little and Z. M. Yuan: Low-dose radiation-induced senescent stromal fibroblasts render nearby breast cancer cells radioresistant. Radiat Res, 172(3), 306-13 (2009)

  • [146]P. C. Wu, Q. Wang, L. Grobman, E. Chu and D. Y. Wu: Accelerated cellular senescence in solid tumor therapy. Exp Oncol, 34(3), 298-305 (2012)

  • [147]R. Sidi, G. Pasello, I. Opitz, A. Soltermann, M. Tutic, H. Rehrauer, W. Weder, R. A. Stahel and E. Felley-Bosco: Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. Eur J Cancer, 47(2), 326-32 (2011)

  • [148]S. D. Tyner, S. Venkatachalam, J. Choi, S. Jones, N. Ghebranious, H. Igelmann, X. Lu, G. Soron, B. Cooper, C. Brayton, S. H. Park, T. Thompson, G. Karsenty, A. Bradley and L. A. Donehower: p53 mutant mice that display early ageing-associated phenotypes. Nature, 415(6867), 45-53 (2002)

  • [149]A. M. Haugstetter, C. Loddenkemper, D. Lenze, J. Grone, C. Standfuss, I. Petersen, B. Dorken and C. A. Schmitt: Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer, 103(4), 505-9 (2010)

  • [150]L. T. Vassilev, B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi and E. A. Liu: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303(5659), 844-8 (2004)

  • [151]A. Ventura, D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. Newman, E. E. Reczek, R. Weissleder and T. Jacks: Restoration of p53 function leads to tumour regression in vivo. Nature, 445(7128), 661-5 (2007)

  • [152]V. J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K. G. Wiman and G. Selivanova: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med, 8(3), 282-8 (2002)

  • [153]Y. Peng, C. Li, L. Chen, S. Sebti and J. Chen: Rescue of mutant p53 transcription function by ellipticine. Oncogene, 22(29), 4478-87 (2003)

  • [154]H. C. Chuang, L. P. Yang, A. L. Fitzgerald, A. Osman, S. H. Woo, J. N. Myers and H. D. Skinner: The p53-reactivating small molecule RITA induces senescence in head and neck cancer cells. PLoS One, 9(8), e104821 (2014)

  • [155]K. M. Burchett, Y. Yan and M. M. Ouellette: Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS One, 9(1), e85155 (2014)

  • [156]A. E. Hochreiter, H. Xiao, E. M. Goldblatt, S. M. Gryaznov, K. D. Miller, S. Badve, G. W. Sledge and B. S. Herbert: Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res, 12(10), 3184-92 (2006)

  • [157]S. Chakraborty, M. Jain, A. R. Sasson and S. K. Batra: MUC4 as a diagnostic marker in cancer. Expert Opin Med Diagn, 2(8), 891-910 (2008)

  • [158]M. A. Macha, S. Rachagani, P. Pai, S. Gupta, W. M. Lydiatt, R. B. Smith, S. L. Johansson, S. M. Lele, S. S. Kakar, J. H. Lee, J. Meza, A. K. Ganti, M. Jain and S. K. Batra: MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway. Oncogene, 34(13), 1698-708 (2015)

  • [159]Y. Meng, E. V. Efimova, K. W. Hamzeh, T. E. Darga, H. J. Mauceri, Y. X. Fu, S. J. Kron and R. R. Weichselbaum: Radiation-inducible immunotherapy for cancer: senescent tumor cells as a cancer vaccine. Mol Ther, 20(5), 1046-55 (2012)

  • [160]I. B. McInnes and G. Schett: The pathogenesis of rheumatoid arthritis. N Engl J Med, 365(23), 2205-19 (2011)

  • [161]K. Taniguchi, H. Kohsaka, N. Inoue, Y. Terada, H. Ito, K. Hirokawa and N. Miyasaka: Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med, 5(7), 760-7 (1999)

  • [162]J. P. Coppe, F. Rodier, C. K. Patil, A. Freund, P. Y. Desprez and J. Campisi: Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem, 286(42), 36396-403 (2011)

  • [163]V. Bours, G. Bonizzi, M. Bentires-Alj, F. Bureau, J. Piette, P. Lekeux and M. Merville: NF-kappaB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology, 153(1-3), 27-38(2000)

  • [164]R. M. Laberge, L. Zhou, M. R. Sarantos, F. Rodier, A. Freund, P. L. de Keizer, S. Liu, M. Demaria, Y. S. Cong, P. Kapahi, P. Y. Desprez, R. E. Hughes and J. Campisi: Glucocorticoids suppress selected components of the senescence-associated secretory phenotype. Aging Cell, 11(4), 569-78 (2012)

  • [165]H. D. Skinner, V. C. Sandulache, T. J. Ow, R. E. Meyn, J. S. Yordy, B. M. Beadle, A. L. Fitzgerald, U. Giri, K. K. Ang and J. N. Myers: TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res, 18(1), 290-300 (2012)

  • [166]O. Moiseeva, X. Deschenes-Simard, E. St-Germain, S. Igelmann, G. Huot, A. E. Cadar, V. Bourdeau, M. N. Pollak and G. Ferbeyre: Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-kappaB activation. Aging Cell, 12(3), 489-98 (2013)

  • [167]R. M. Memmott, J. R. Mercado, C. R. Maier, S. Kawabata, S. D. Fox and P. A. Dennis: Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila), 3(9), 1066-76 (2010)

  • [168]M. Pollak: Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila), 3(9), 1060-5 (2010)

  • [169]K. Bhalla, B. J. Hwang, R. E. Dewi, W. Twaddel, O. G. Goloubeva, K. K. Wong, N. K. Saxena, S. Biswal and G. D. Girnun: Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila), 5(4), 544-52 (2012)

  • [170]M. N. Pollak: Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov, 2(9), 778-90 (2012)

  • [171]S. Uwe: Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol, 75(8), 1567-79 (2008)

  • [172]Y. Yamamoto and R. B. Gaynor: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest, 107(2), 135-42 (2001)

  • [173]B. Sehnert, H. Burkhardt, J. T. Wessels, A. Schroder, M. J. May, D. Vestweber, J. Zwerina, K. Warnatz, F. Nimmerjahn, G. Schett, S. Dubel and R. E. Voll: NF-kappaB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-kappaB in immune-mediated diseases. Proc Natl Acad Sci U S A, 110(41), 16556-61 (2013)

  • [174]M. A. Brach, R. Hass, M. L. Sherman, H. Gunji, R. Weichselbaum and D. Kufe: Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest, 88(2), 691-5 (1991)

  • [175]N. Kozakai, E. Kikuchi, M. Hasegawa, E. Suzuki, H. Ide, A. Miyajima, Y. Horiguchi, J. Nakashima, K. Umezawa, N. Shigematsu and M. Oya: Enhancement of radiosensitivity by a unique novel NF-kappaB inhibitor, DHMEQ, in prostate cancer. Br J Cancer, 107(4), 652-7 (2012)

  • [176]G. Matsumoto, J. Namekawa, M. Muta, T. Nakamura, H. Bando, K. Tohyama, M. Toi and K. Umezawa: Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res, 11(3), 1287-93 (2005)

  • [177]H. Takatsuna and K. Umezawa: Screening of bioactive metabolites for pancreatic regeneration chemotherapy. Biomed Pharmacother, 58(10), 610-3 (2004)

  • [178]D. V. Starenki, H. Namba, V. A. Saenko, A. Ohtsuru, S. Maeda, K. Umezawa and S. Yamashita: Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res, 10 (20), 6821-9 (2004)

  • [179]J. S. Tilstra, A. R. Robinson, J. Wang, S. Q. Gregg, C. L. Clauson, D. P. Reay, L. A. Nasto, C. M. St Croix, A. Usas, N. Vo, J. Huard, P. R. Clemens, D. B. Stolz, D. C. Guttridge, S. C. Watkins, G. A. Garinis, Y. Wang, L. J. Niedernhofer and P. D. Robbins: NF-kappaB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest, 122(7), 2601-12 (2012)

  • [180]J. H. Cho, M. Dimri and G. P. Dimri: MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence. J Biol Chem, 290(16), 10555-67 (2015)

  • [181]K. C. Chan, C. M. Ting, P. S. Chan, M. C. Lo, K. W. Lo, J. E. Curry, T. Smyth, A. W. Lee, W. T. Ng, G. S. Tsao, R. N. Wong, M. L. Lung and N. K. Mak: A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol Cancer, 12(1), 128 (2013)

  • [182]A. Ernst, H. Anders, H. Kapfhammer, M. Orth, R. Hennel, K. Seidl, N. Winssinger, C. Belka, S. Unkel and K. Lauber: HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. Cancer Lett, 365(2), 211-22 (2015)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2017Review

Interconnection between DNA damage, senescence, inflammation, and cancer

Roland Wunderlich 1, Paul-Friedrich Ruehle 2, Lisa Deloch 2, Kristian Unger 1, Julia Hess 1, Horst Zitzelsberger 1, Kirsten Lauber 3, Benjamin Frey 2, Udo S. Gaipl 2,*
Affiliations
Article Info

1 Research Unit Radiation Cytogenetics, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Neuherberg, Germany

2 Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

3 Department of Radiation Oncology, Ludwig-Maximilians-Universitaet Muenchen, Marchioninistrasse 15, 81377 Munich, Germany

Abstract

In order to deal with endogenous and exogenous factors, including radiation or pathogens, cells evolved different strategies. This includes highly complex processes such as DNA damage response, senescence, cell death, and inflammatory reactions. Recent research indicates an interconnection between the mentioned cellular pathways whilst all of them seem to play a role in induction and progression, but also the prevention of cancerous diseases and therefore qualify for potential prevention and treatment strategies. On the basis of their pivotal functions in cancer biology in general, each of the cellular processes represents promising single therapeutic targets. Further, due to their strong interconnection, targeting all of them in a multimodal approach could be another promising strategy to treat cancer. We, therefore, review the mechanisms of DNA damage induction, detection and repair as well as the induction of cell death. Further, features of senescence and mechanism of inflammation induction and abrogation are outlined. A special focus is set on how senescence and inflammation are related to diseases and how targeting them, could contribute to improvement of cancer therapies.

Keywords

  • Review
  • Radiation
  • DNA Damage
  • Senescence
  • SASP
  • Inflammation
  • Cancer
  • Review

References